Skip to main content
. Author manuscript; available in PMC: 2014 Mar 19.
Published in final edited form as: Mol Cancer Ther. 2012 Mar 12;11(5):1071–1081. doi: 10.1158/1535-7163.MCT-11-0852

Figure 3. A431 tumors are responsive to gefitinib in vivo.

Figure 3

A) Tumor growth curve for A431 xenografts in animals treated with 50 mg/kg gefitinib or left untreated and tumor growth curve for gefitinib-resistant tumors (A431-ZDR) in animals treated with 50 mg/kg gefitinib or left untreated. B) Tumor lysates were generated from A431 xenografts and analyzed by immunoblot for the 16 proteins in the panel. Lysates were fractionated to enrich for soluble and insoluble proteins.